Advanced Accelerator Application SA(ADR)(NASDAQ:AAAP) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during Pre-market on Nov 28, 2016. Company reported revenue of $30.03M. Analysts estimated a revenue of $27.34M. The revenues were $2.69M or 9.84% above the estimates. Earnings per share were $-0.09. The reported EPS was above estimates by $0.02 or 18.18%. Analysts had estimated an EPS of $-0.11.
Advanced Accelerator Applications SA is a radiopharmaceutical company that develops produces and sells molecular nuclear medicine (MNM) diagnostic and therapeutic products. The Companys lead therapeutic candidate Lutathera is being developed for the treatment of midgut neuroendocrine tumors (NETs). The Company has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its products in clinical development include Lutathera Somakit and Annexin V-128. The Companys commercial products include Gluscan /Gluscan 500/Barnascan IASOflu IASOdopa IASOcholine MIBITEC/Adamibi and Leukokit. Lutathera is a solution of a Lu-177-labeled analogue of somatostatin a hormone that acts as a regulator of the endocrine system. Somakit is the Companys companion PET diagnostic product candidate for Lutathera. Annexin V-128 is a SPECT diagnostic candidate for the assessment of apoptotic and necrotic processes.